Paladin Pharma and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Public Funding of XCOPRI® (cenobamate tablets)
MONTREAL, April 14, 2025 /CNW/ -- Paladin Pharma is pleased to announce the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public funding of XCOPRI® (cenobamate tablets) as adjunctive therapy in the management of focal seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.1
'We are pleased to have successfully concluded the negotiation process with the pCPA,' said Livio Di Francesco, Vice President & General Manager of Paladin Pharma. 'This is a significant milestone to ensure that appropriate Canadian epilepsy patients have broad and equitable access to XCOPRI, and it is exciting news for the epilepsy community across Canada.'
Since launch, the Paladin team has already achieved early access for XCOPRI through private payer reimbursement, with approximately 85% of privately insured lives in Canada having access to the treatment.
The next step in the public reimbursement process will be for provincial, territorial, and federal government organizations to make their respective final decisions on public reimbursement for their regions. Paladin looks forward to working with each of them to make XCOPRI available as soon as possible through public drug plans.
'We hope the jurisdictions move as quickly as possible,' added Di Francesco. 'Uncontrolled epilepsy can have a significant impact on a patient's life, and we look forward to the day when all appropriate patients in Canada can have access to this important treatment option.'
About Epilepsy 2-4
Epilepsy is a chronic neurological condition affecting ~300,000 Canadians. It is characterized by recurrent, unprovoked seizures. While there are many different types of seizures, they can be grouped into two broad categories – generalized seizures and focal seizures – based on where in the brain the seizure activity starts. Focal seizures (also called partial-onset seizures) affect ~60% of people with epilepsy. While many people with epilepsy respond to anti-seizure medication, ~30% of patients continue to experience seizures, despite treatment with currently available medication options.
About XCOPRI
XCOPRI received Health Canada approval in June 2023 for use as adjunctive therapy in the management of focal seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. It is taken orally, once daily.5
XCOPRI is a new generation of anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK Life Science. It is a novel molecule with a dual mechanism of action. In pre-clinical studies, XCOPRI has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a modulator of the γ-aminobutyric acid (GABAA) ion channel.5-6 The efficacy and safety of XCOPRI for the treatment of adults with uncontrolled partial-onset seizures (also known as focal-onset seizures) were assessed in two randomized, placebo-controlled, double-blind clinical trials (C013 and C017).6-7 The long-term safety of cenobamate in this population has been studied in an open-label safety study (C021).8
During Studies C013 and C017, a total of 441 patients were exposed to XCOPRI. In both studies, the primary efficacy endpoint was median percent reduction from baseline in seizure frequency per 28 days. The key secondary endpoint was responder rates, defined as the proportion of patients with 50% or greater reduction in seizure frequency. XCOPRI significantly reduced seizure frequency and demonstrated a significantly higher ≥50% responder rate compared to placebo. In Study C013, 28.3% of patients in the cenobamate group reported being seizure free during the maintenance phase (placebo: 8.8%).
Consult the Product Monograph for complete efficacy and safety information.
Cenobamate is currently marketed in the U.S. as XCOPRI® and in Europe under the trademark ONTOZRY®.
About Paladin Pharma
Paladin Pharma Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing, medical, and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo, Inc. For more information visit www.paladin-pharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Mr. Di Francesco and any statements relating to marketing approval, public funding and reimbursement, product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plan,' 'will,' 'may,' 'look forward,' 'intends,' 'guidance,' 'future,' 'potential' or similar expressions are forward-looking statements. Because these statements reflect Paladin's or Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Paladin and Endo may not currently be able to predict. Although Paladin and Endo believe that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the public funding processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading 'Risk Factors' in Endo's most recent Form 10-K and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A.
References:
SOURCE Paladin Pharma Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Union says lawsuit over federal pesticide safety rules aims to protect agricultural workers
A union representing agricultural workers across the country says the information workers get when handling pesticides is insufficient. It is suing the federal government with the aim of forcing it to enforce rules, it says, already exist. "It's high time for the federal government to do what it's already committed to do and that's what this case is about," Derek Johnstone of the United Food and Commercial Workers (UFCW) said. "It's also another opportunity for us as Canadians to look at something as basic a food worker knowing what he or she or they are handling and not having that information, so how did we get here?" The union held an information session about safety sheets in Leamington, Ont., on Sunday. Thousands of workers come from countries such as Mexico and Guatemala to work in greenhouses in the southwestern Ontario community each year. The UFCW launched its lawsuit against the federal government in federal court last week. It argues that safety information including "material safety data sheets" are a condition of registering pest control products and that those sheets must be provided to workplaces that use the products. The application by the union states that the government has taken the "unreasonable position that the provision of material safety data sheets to workplaces is voluntary" and that by not enforcing the requirement, it is failing to protect agricultural workers. "It's unfortunate that the government has taken to using the term voluntary when it comes to providing basic information about chemicals and pesticides that workers handle," Johnstone said. "This is not a choice. This is not a recommendation by government. This is a right enshrined in health and safety law. The right to know is the first step when it comes to a worker's health and safety rights." Health Canada refused comment to the CBC on the lawsuit, citing pending litigation. Sean O'Shea of Ecojustice, an environmental law charity whose lawyers are listed on the application, says data sheets provide information about possible risks of pest control products and protective measures one should take when using them. "It might require you to wear (personal protective equipment) to discard of any clothes you're wearing before you return to your home," he said. "It might say that it shouldn't be mixed with another chemical or another pesticide because it's not just the use of one pesticide. The problem is the use of several pesticides can have cumulative effects when chemicals are mixed together."
Yahoo
an hour ago
- Yahoo
Canadian wildfires prompt another air quality alert for coastal Maine
Jun. 9—The Maine Department of Environmental Protection says smoke from Canadian wildfires is again impacting air quality in Maine. Ground-level pollution concentrations in southwest coastal Maine were in the "unhealthy for sensitive groups" level Sunday and have continued in that range into Monday. The elevated level is most likely to impact children, older adults, and people with respiratory or heart disease. While the pollution concentration level may drop during the day Monday, another plume of wildfire smoke is expected to move in from the east and reach the Maine and New Hampshire coast by afternoon, according to the DEP. That plume from the western Canadian wildfires broke off over Newfoundland and Labrador and has now moved south into Nova Scotia. The smoke is expected to move move out Tuesday, but it could return in the coming days as wildfires continue to burn across Canada, the DEP said. The air quality could cause people with asthma, bronchitis, chronic obstructive pulmonary disease or other conditions to experience reduced lung function and irritation, according to the DEP. Officials say it is possible that even healthy adults who exert themselves outside could notice side effects, such as coughing, shortness of breath, throat irritation and mild chest pain. People can protect themselves by avoiding strenuous outdoor activity, closing windows, and circulating indoor air with a fan or air conditioner. Last week, smoke from the Canadian wildfires led the DEP to issue a similar air quality alert for much of Maine's coastline Wednesday and Thursday. Dozens of wildfires burning in the western provinces of Manitoba and Saskatchewan, including one more than twice the size of Los Angeles, have forced thousands of Canadians to evacuate their homes in recent weeks. Copy the Story Link
Yahoo
2 hours ago
- Yahoo
We Need to Talk About Erectile Dysfunction: 38% of Canadian Men Don't Know You Need a Prescription for ED Medication
– This Men's Health Week, Phoenix is addressing misconceptions around erectile dysfunction to raise awareness for treatment and break the social stigma – TORONTO, June 09, 2025--(BUSINESS WIRE)--For Men's Health Week (June 9 to 15), Phoenix, Canada's leading digital health clinic for men, is raising awareness to break the stigma around erectile dysfunction (ED), a medical condition that affects almost half (49.4%) of Canadian men aged 40 to 88. ED is a medical condition that prevents the ability to get and maintain an erection sufficient for sexual intercourse, with a range of potential causes that could each contribute to the condition, including age, medications, injury, and lifestyle. Despite its prevalence, Phoenix's survey of more than 1,500 Canadians found that there is a significant lack of awareness around ED and its treatment, likely contributing to stigma surrounding the condition. CANADIANS UNDERESTIMATE THE REACH OF ED Despite nearly half of Canadian men over 40 being affected, ED's prevalence is underestimated, driving undue stigma. In fact, almost half of Canadians (45%) think that ED affects less than 40 per cent of men 40+. Twenty-seven per cent of Canadians think it affects less than 30 per cent of men 40+. While Canadians underestimate the prevalence of ED in middle-aged and older men, many are also unaware that the condition can also impact younger men. The survey found that 64 per cent of Canadians don't know that men aged 35 and younger can experience ED. That percentage grows as you look at younger men, with 71% of Canadians unaware that men aged 18 to 25 can be affected. This common misconception can contribute to the stigma around experiencing ED as a younger man, making it more difficult for those struggling to seek care. "ED is a medical condition that men of all ages can experience. There shouldn't be anything awkward about it, but there is. We're trying to change that," says Kevin Bache, co-founder and co-CEO of Phoenix. "While it may feel uncomfortable, men need to understand what the condition entails, and not shy away from being proactive in discussing it with a doctor. The sooner you get started, the better your chances are at finding mental and physical relief." WIDESPREAD MISUNDERSTANDING OF ED MEDICATION Treatment for ED and its underlying cause can vary greatly depending on a patient's prognosis, however, medication is a common and effective treatment. Despite this fact, Phoenix's survey found 18 per cent of men are unsure if ED is treatable with medication, revealing a lack of awareness that may leave many suffering needlessly. The data also highlighted a concerning gap in awareness that ED medication requires a prescription. Thirty-eight per cent of men are unsure or don't think they need a prescription to purchase medication, such as Viagra, for ED. However, the lack of awareness is most significant among younger Canadians. About three in five Gen Z (59%) don't know that you need a prescription for ED medication: 32 per cent are unsure, and 27 per cent don't think you need a prescription at all. It is important that Canadians know that ED medication requires a prescription from a medical professional, as they may otherwise be vulnerable to purchasing unauthorized sexual enhancement products sold over the counter, which Health Canada warns could pose serious health risks. "It's no surprise that people aren't aware of the prevalence of ED – it just doesn't get talked about enough. But the good news is, there are treatment options, and with more openness and awareness, more people can seek support immediately," says Gavin Thompson, co-founder and co-CEO of Phoenix. "We built Phoenix to change that. Our mission is simple: make expert care easy to access – fast, discreet, and doctor-led. We're building a future where men take charge of their health with confidence." WHAT CANADIANS NEED TO KNOW ABOUT ED ED can affect men at any age, but it becomes more common as you get older. ED is more common than you may think, affecting almost half of Canadian men aged 40 to 88. Many factors can cause ED, including: low levels of testosterone, nervous dysfunction, blood flow complications, medications, medical conditions, lifestyle factors, obesity, diet, drug abuse, smoking, and emotional or psychological complications. ED is highly treatable, but the first step is consulting a medical professional. Treatment for erectile dysfunction and its underlying cause can vary greatly, making it important to consult a medical professional to receive a diagnosis and devise an effective treatment strategy. ED medication requires a prescription from a medical professional. Phoenix is currently available in Ontario, Alberta, British Columbia, Saskatchewan, Manitoba, Nova Scotia, New Brunswick, PEI, and Newfoundland. To learn more about Phoenix's ED support, visit ABOUT PHOENIX Phoenix is Canada's leading digital health clinic for men, specializing in three areas of treatment – erectile dysfunction, weight loss, and hair loss. The telehealth platform facilitates access to licensed Canadian physicians, treatment options, and free, discreet shipping of prescription medication from coast to coast. Visit to learn more. SURVEY METHODOLOGY These findings are from a survey conducted by Phoenix from May 20th to May 22nd, 2025, among a representative sample of 1509 online Canadians who are members of the Angus Reid Forum. The survey was conducted in English and French. For comparison purposes only, a probability sample of this size would carry a margin of error of +/-2.53 percentage points, 19 times out of 20. View source version on Contacts MEDIA Anne-Marie TrembleSenior Account Manager, Talk Shop Mediaannemarie@ 613-914-3551
